A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

This study is a very early investigation into a new drug called IPH5301. It's designed for people with advanced cancers that have spread to other parts of the body, such as breast, stomach, lung, and ovarian cancers. Because it's a 'first-in-human' study, it means that this is the first time IPH5301 is being given to people. The main purpose is to carefully check if the drug is safe and to figure out the right amount (dose) to give.

The study will happen in two main parts. In the first part, a small group of patients will receive IPH5301, starting with very low doses, which will be slowly increased. This helps the doctors find the highest dose that can be given without causing too many serious side effects, known as the 'maximum tolerated dose,' and also recommend a dose for future studies. The second part will focus on a specific group of breast cancer patients whose cancer has too much of a protein called HER2. These patients will receive IPH5301 along with standard chemotherapy and another drug called trastuzumab. The aim here is to see how safe and effective this combination is, and to help choose the best dose for future, larger studies.

This research is a vital step in developing new treatments for cancer. It helps doctors understand how IPH5301 works in the body, what side effects it might have, and if it could potentially help patients when combined with other medicines. Every new cancer treatment goes through careful steps like this to ensure it's safe and has the potential to be helpful.